BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman Sells 611 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 611 shares of the stock in a transaction on Monday, September 16th. The shares were sold at an average price of $25.12, for a total value of $15,348.32. Following the completion of the sale, the chief financial officer now owns 124,388 shares in the company, valued at approximately $3,124,626.56. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Troy Wichterman also recently made the following trade(s):

• On Wednesday, August 21st, Troy Wichterman sold 142 shares of BioLife Solutions stock. The shares were sold at an average price of $25.61, for a total transaction of $3,636.62.
• On Thursday, July 11th, Troy Wichterman sold 828 shares of BioLife Solutions stock. The stock was sold at an average price of $20.54, for a total transaction of $17,007.12.

BioLife Solutions Trading Up 1.2 %

Shares of BLFS stock opened at $23.72 on Thursday. The stock has a 50 day simple moving average of $23.98 and a 200 day simple moving average of $20.83. BioLife Solutions, Inc. has a 1 year low of $8.92 and a 1 year high of $26.73. The company has a current ratio of 2.86, a quick ratio of 1.81 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.09 billion, a P/E ratio of -16.70 and a beta of 1.87.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.08. BioLife Solutions had a negative net margin of 59.88% and a negative return on equity of 10.75%. The firm had revenue of $28.33 million for the quarter, compared to the consensus estimate of $23.80 million. On average, research analysts predict that BioLife Solutions, Inc. will post -0.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on BLFS shares. Craig Hallum increased their price target on shares of BioLife Solutions from $23.00 to $30.00 and gave the company a “buy” rating in a report on Monday, August 12th. TD Cowen lifted their price target on BioLife Solutions from $20.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, July 17th. Finally, Northland Securities upped their price objective on BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.20.

Hedge Funds Weigh In On BioLife Solutions

Several institutional investors and hedge funds have recently added to or reduced their stakes in BLFS. Meros Investment Management LP increased its holdings in shares of BioLife Solutions by 1.7% during the second quarter. Meros Investment Management LP now owns 399,803 shares of the medical equipment provider’s stock worth $8,568,000 after buying an additional 6,586 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in BioLife Solutions by 5.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,825 shares of the medical equipment provider’s stock worth $296,000 after purchasing an additional 753 shares in the last quarter. Squarepoint Ops LLC bought a new position in BioLife Solutions in the second quarter valued at about $1,041,000. Fred Alger Management LLC raised its position in BioLife Solutions by 6.0% in the second quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock valued at $33,841,000 after purchasing an additional 88,840 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of BioLife Solutions during the second quarter valued at about $229,000. Institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.